AIM ImmunoTech Inc.
New York Stock Exchange ArcaRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- AIM ImmunoTech Inc. is a leading immuno-pharmaceutical company dedicated to the research and development of innovative therapies for a variety of cancers, viral infections, and immune system disorders. The company's flagship investigational drug, Ampligen (rintatolimod), is a synthetic double-stranded RNA molecule operating as a Toll-like Receptor 3 (TLR3) agonist. Ampligen is being explored in multiple clinical trials for various solid tumor cancers, including a primary focus on metastatic pancreatic cancer, where it is being evaluated in combination with other immunotherapies. It is also undergoing assessment for applications in conditions such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-COVID conditions, with positive preliminary data reported in these areas. Ampligen is commercially approved in Argentina for treating severe chronic fatigue syndrome. Beyond Ampligen, the company offers Alferon N Injection, a natural alpha interferon formulation approved for treating refractory genital warts. AIM ImmunoTech actively engages in strategic collaborations with major cancer research centers and has secured patents for Ampligen's use in combination therapies for various cancers and for long-COVID treatments in key markets like Japan and Europe. Headquartered in Ocala, Florida, the company, formerly known as Hemispherx Biopharma, Inc., rebranded to AIM ImmunoTech Inc. in 2019, reflecting its core mission in amplified immunological modulation. The company continues to advance its pipeline with an emphasis on addressing unmet medical needs in oncology and debilitating chronic conditions.
Company News
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039
Metals One partner rejects claim that Barbrook mine deal has failed
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now' On-Demand Conference
Alien Metals shares rise 4% after bonanza-grade silver results
Thruvision shares rise over 14% after Canadian government order
Tower Resources tops up working capital as farm-out moves closer to completion
Cavendish lifts Optima Health target as annual profit beats forecasts
Moog Celebrates 75 Years of Innovation with New Advanced Integrated Manufacturing Facility, Workforce Investment and STEM Scholarship Initiative
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense' Article
Bravura Solutions shares climb as AIM newbie marks 76% jump in cash earnings
Thruvision shares surge 46% to 0.91p on £3m Asian airport contract
Major boon predicted for Jersey Oil & Gas as bullish broker repeats Buy rating
AIM ImmunoTech Ahead of Schedule on ‘Last Dose' DURIPANC Critical Clinical Inflection Point
Admission to Trading on the Main Market and AIM Cancellation
Cavendish sees 18-fold upside at 88 Energy on Alaska prospect scale
Seeing Machines wins European carmaker deal as EU driver monitoring rules come into force
CelLBxHealth builds £3.5m weighted pipeline as revenue growth target held
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program